Cosmo Pharmaceuticals N.V. | Mutual Funds
Mutual Funds that own Cosmo Pharmaceuticals N.V.
Vanguard International Explorer Fund
500,000
3.33%
-155,000
1.59%
06/30/2018
AMG Substanzwerte Schweiz
401,700
2.67%
32,121
8.03%
12/31/2017
Government Pension Fund - Global (The)
105,921
0.7%
-3,325
0%
12/31/2017
Vanguard Total International Stock Index Fund
100,795
0.67%
0
0%
07/31/2018
Baillie Gifford Overseas Growth Fund - European Fund
64,376
0.43%
4,183
1.62%
04/30/2018
UBS (CH) Equity Fund - Small Caps Switzerland
62,107
0.41%
1,055
2.58%
12/29/2017
UBS (CH) Institutional Fund - Small & Mid Cap Equities Switzer
53,498
0.36%
839
0.77%
12/29/2017
CSIF Switzerland Total Market Index
48,346
0.32%
-413
0.08%
05/31/2018
UBS (CH) Equity Fund - Swiss High Dividend
41,937
0.28%
0
1.04%
01/31/2018
Vanguard Developed Markets Index Fund
39,926
0.27%
0
0.01%
07/31/2018
| Address |
Riverside II
Dublin Dublin 2
Ireland
|
|
Employees
|
- |
| Website |
http://www.cosmopharma.com |
| Updated |
07/08/2019 |
| Cosmo Pharmaceuticals NV engages in the development, manufacturing and distribution of treatments for gastrointestinal diseases, endoscopy, colorectal cancer diagnosis, and colonoscopy. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland. . |
